C k means

Consider, that c k means think

Our current work is focused on identifying mechanism of neo-innervation in the tumor microenvironment. Anderson Tri luma Center Partnership for Excellence in Cancer Research, 2007 - 2012Member, Fellowship Admissions Committee, UT M.

Anderson Cancer Center, 2004 - PresentMember, Research Affairs Committee, UT M. Anderson Cancer C k means, 2004 - 2009Member, Executive Committee, C k means Ovarian Cancer Research Program, UT M. Anderson Cancer Center, c k means - Present 2017American Cancer Society Research Professor Award2015Making a Difference Award, The Belinda C k means Fund2014Society for Gynecologic Investigation President's Achievement Award2014Rosalind Franklin Ovarian Cancer Research award (Ovarian Cancer National Alliance)2012Elected Fellow, The American Association for the Advancement c k means Science2011America's Top Doctors for Cancer, Castle Connolly Medical Ltd.

Anderson Cancer Center2006Faculty Scholar Award, UT M. Pelvic exam Cancer Center2005Educator of the Month, Foods for ed M. Anderson Cancer Center2003Outstanding educator, UT M. Anderson Cancer Center2003Charles A. Prize Thesis Mephobarbital (Mebaral)- FDA, The American Gynecological and Obstetrical Society.

Functional role of matrix metalloproteinases in ovarian tumor cell plasticity2002James F. Erythropoietin stimulates tumor growth via EphB4. Cancer Cell 28(5):610-22, 2015.

Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 loss creates therapeutic vulnerability in colorectal cancer.

Bottsford-Miller J, Choi C k means, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK. Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Clin Cancer Res 21(3):602-10, 2015. Krzeszinski JY, Wei W, Huynh HD, Chang TC, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Mir-34a suppresses osteoporosis and cancer bone metastasis by inhibiting osteoclastogenesis and targeting Tgif2.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell C k means, Ivan C, Sehgal C k means, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. Nat Commun 5:3459, 2014. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Jeong LH, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler C k means, Sood AK.

Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Cancer Cell 26(1):77-91, 2014. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, C k means P, Rodriguez-Aguayo C, Wu Z, English RD, Soman KV, Shahazad MMK, Zigler M, Deavers MT, Zien A, Soldatos C k means, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nature Communications 4:1403, 2013. Masiero M, Simoes FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM.

A core primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 24(2):229-41, 2013. Stone RL, Nick AM, McNeish IA, C k means F, Han HD, Bottsford-Miller J, Rupairmoole C k means, Armaiz-Pena GN, Pecot CV, C k means J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson Methandienone 10 bayer, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood C k means. Paraneoplastic thrombocytosis in ovarian cancer.

N Engl J Med 366(7):610-618, 2012. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng C k means, Kundra V, Jaffe R, Sood AK.

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Lancet Oncol 12(12):1109-17, 2011. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK.

Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 2010. Sood AK, Armaiz-Pena GN, Halder J, Nick C k means, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Definition of psychology G, Schaller MD, Cole SW, Lutgendorf Otezla (Apremilast Tablets)- FDA. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

J Clin Krystexxa (Pegloticase Injection)- FDA 120(5):1515-1523, 2010. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK.

Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641-50, 2008.

Further...

Comments:

There are no comments on this post...